Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

Stem cell transplant firms Kiadis and CytoSen join forces

Stem cell transplant firms Kiadis and CytoSen join forces

The NK cell therapy is designed to destroy any remaining malignant cells and reduce the chances that patients relapse. ... With the addition of CytoSen, we can create cell therapy treatments that combine the innate and adaptive arms of the immune

Latest news

More from news
Approximately 5 fully matching, plus 246 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    This adds to the good news for Vertex, which saw AbbVie and Galapagos also post disappointing results for their triple therapy candidate. ... A gene therapy cure for all the world’s CF patients would be a truly remarkable achievement.

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs. ... We estimate the cost [of making a CAR-T cell therapy for a

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    Cell therapy company Cellectis remains an exponent of TALEN, while Bluebird is using a next- generation platform called MegaTals. ... CRISPR can also be used to recreate human genetic diseases by editing DNA in animals and cell lines.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

  • Deal Watch October 2018

    Cell therapy products based on antigen presenting cells. for target‐specific killer CD8 T‐cell responses. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Jean Stéphenne joins the cell therapy company from TiGenix. Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in ... He will be a valuable addition to an

More from appointments
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases.

  • Solaris Health looks at the gene therapy revolution

    And every new therapy will have its own specific challenges depending on the disease it is targeting. ... As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene

  • Training the next generation of biotech leaders

    As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy. ... It brings engineers and people from the life sciences sector into the department to learn about biochemical engineering

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the ... You have this fantastic jewel that nobody really noticed but in the

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics